Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00014131 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Kidney Cancer
A Phase 1 study, sponsored by Lisata Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT00014131 is a Phase 1 study that was terminated before completion, run by Lisata Therapeutics. The registered enrollment target is 9 participants.
The verdict
NCT00014131, a Phase 1 study, was terminated before completion, sponsored by Lisata Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines made from a patient's white blood cells and tumor cells may make the body build an immune response to kill tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients who have recurrent or stage III or stage IV kidney cancer.
Interventions
- BIOLOGICAL Biological/Vaccine: therapeutic autologous dendritic cells.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2001-11 |
| Est. Completion | 2009-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00014131
The ClinicalTrials.gov registry entry for NCT00014131 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lisata Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Biological/Vaccine: therapeutic autologous dendritic cells. is the first listed.
NCT00014131 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00014131 about?
NCT00014131 is a clinical study titled "Vaccine Therapy in Treating Patients With Kidney Cancer". RATIONALE: Vaccines made from a patient's white blood cells and tumor cells may make the body build an immune response to kill tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients who have recurrent or stage III or stage IV kidney cancer.
What is the current status of trial NCT00014131?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2001-11. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00014131?
The interventions under investigation include: Biological/Vaccine: therapeutic autologous dendritic cells. (BIOLOGICAL).
Who is sponsoring clinical trial NCT00014131?
This trial is sponsored by Lisata Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.